Evidence map›Paper›PMID 33569048›Full record

ArticleFrontiers in immunology2020

Regulated Tristetraprolin Overexpression Dampens the Development and Pathogenesis of Experimental Autoimmune Uveitis.

Biying Xu, Jihong Tang, Cancan Lyu, Wambui S Wandu, Deborah J Stumpo, Mary J Mattapallil, Reiko Horai, Igal Gery, Perry J Blackshear, Rachel R Caspi

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Biying XuLaboratory of Immunology, National Eye Institute, NIH, Bethesda, MD, United States.
Jihong TangLaboratory of Immunology, National Eye Institute, NIH, Bethesda, MD, United States.
Cancan LyuLaboratory of Immunology, National Eye Institute, NIH, Bethesda, MD, United States.
Wambui S WanduLaboratory of Immunology, National Eye Institute, NIH, Bethesda, MD, United States.
Deborah J StumpoSignal Transduction Laboratory, National Institute of Environmental Health Sciences, Research Triangle Park, NC, United States.
Mary J MattapallilLaboratory of Immunology, National Eye Institute, NIH, Bethesda, MD, United States.
Reiko HoraiLaboratory of Immunology, National Eye Institute, NIH, Bethesda, MD, United States.
Igal GeryLaboratory of Immunology, National Eye Institute, NIH, Bethesda, MD, United States.
Perry J BlackshearSignal Transduction Laboratory, National Institute of Environmental Health Sciences, Research Triangle Park, NC, United States.
Rachel R CaspiLaboratory of Immunology, National Eye Institute, NIH, Bethesda, MD, United States.
National Eye Institute · USDuke Medical Center · USNational Institute of Environmental Health Sciences · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-infectious uveitis, a common cause of blindness in man, is often mediated by autoimmunity, a process in which cytokines play major roles. The biosynthesis and secretion of pro-inflammatory cytokines are regulated in part by tristetraprolin (TTP), an endogenous anti-inflammatory protein that acts by binding directly to specific sequence motifs in the 3'-untranslated regions of target mRNAs, promoting their turnover, and inhibiting synthesis of their encoded proteins. We recently developed a TTP-overexpressing mouse (TTPΔARE) by deleting an AU-rich element (ARE) instability motif from the TTP mRNA, resulting in increased accumulation of TTP mRNA and protein throughout the animal. Here, we show that homozygous TTPΔARE mice are resistant to the induction of experimental autoimmune uveitis (EAU) induced by interphotoreceptor retinoid-binding protein (IRBP), an established model for human autoimmune (noninfectious) uveitis. Lymphocytes from TTPΔARE mice produced lower levels of the pro-inflammatory cytokines IFN-γ, IL-17, IL-6, and TNFα than wild type (WT) mice. TTPΔARE mice also produced lower titers of antibodies against the uveitogenic protein. In contrast, TTPΔARE mice produced higher levels of the anti-inflammatory cytokine IL-10, and had higher frequencies of regulatory T-cells, which, moreover, displayed a moderately higher per-cell regulatory ability. Heterozygous mice developed EAU and associated immunological responses at levels intermediate between homozygous TTPΔARE mice and WT controls. TTPΔARE mice were able, however, to develop EAU following adoptive transfer of activated WT T-cells specific to IRBP peptide 651-670, and naïve T-cells from TTPΔARE mice could be activated by antibodies to CD3/CD28. Importantly, TTPΔARE antigen presenting cells were significantly less efficient compared to WT in priming naïve T cells, suggesting that this feature plays a major role in the dampened immune responses of the TTPΔARE mice. Our observations demonstrate that elevated systemic levels of TTP can inhibit the pathogenic processes involved in EAU, and suggest the possible use of TTP-based treatments in humans with uveitis and other autoimmune conditions.

Indexed as

AnimalsAutoimmune DiseasesFemaleGene Knock-In TechniquesMaleMiceMice, Inbred C57BLNervous System Autoimmune Disease, ExperimentalTristetraprolinUveitisTristetraprolinZfp36 protein, mouseautoimmunityexperimental autoimmune uveitis (EAU)IFNγIL-17immunoregulation, tristetraprolin (TTP)inflammatory cytokine

Identifiers

PMID33569048
PMCPMC7868398
OpenAlexW3121363201

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.